Growing significance of myeloperoxidase in non-infectious diseases

被引:78
作者
Hoy, A
Leininger-Muller, B
Kutter, D
Siest, G
Visvikis, S
机构
[1] Ctr Med Prevent, INSERM U525, F-54501 Nancy, France
[2] Labs Reunis Kutter Lieners Hastert Junglinster, Luxembourg, Luxembourg
[3] Fac Pharm Nancy, INSERM U525, Nancy, France
关键词
myeloperoxidase; diseases; marker; therapeutic target;
D O I
10.1515/CCLM.2002.002
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Myeloperoxidase (MPO) is a glycoprotein released by activated polymorphonuclear neutrophils, which takes part in the defense of the organism through production of hypochlorous acid (HOCI), a potent oxidant. Since the discovery of MPO deficiency, initially regarded as rare and restricted to patients suffering from severe infections, MPO has attracted clinical attention. The development of new technologies allowing screening for this defect has permitted new advances in the comprehension of underlying mechanisms. Apart from its implications for host defense, the expression of MPO restricted to myeloid precursors makes MPO mRNA a good marker of acute myeloid leukemia. In addition, during the last few years, involvement of MPO has been described in numerous diseases such as atherosclerosis, lung cancer, Alzheimer's disease and multiple sclerosis. Both strong oxidative activity and MPO genetic polymorphism have been involved. This review summarizes the broad range of diseases involving MPO and points out the possible use of this protein as a new clinical marker and a future therapeutic target.
引用
收藏
页码:2 / 8
页数:7
相关论文
共 66 条
[31]   Clinical manifestation of myeloperoxidase deficiency [J].
Lanza, F .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1998, 76 (10) :676-681
[32]  
Le Marchand L, 2000, CANCER EPIDEM BIOMAR, V9, P181
[33]  
London SJ, 1997, CANCER RES, V57, P5001
[34]   Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions -: Colocalization of myeloperoxidase and hypochlorite-modified proteins [J].
Malle, E ;
Waeg, G ;
Schreiber, R ;
Gröne, EF ;
Sattler, WS ;
Gröne, HJ .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (14) :4495-4503
[35]   ACTIVATION OF (+/-)-TRANS-7,8-DIHYDROXY-7,8-DIHYDROBENZO[A]PYRENE TO DIOLEPOXIDES BY HUMAN POLYMORPHONUCLEAR LEUKOCYTES OR MYELOPEROXIDASE [J].
MALLET, WG ;
MOSEBROOK, DR ;
TRUSH, MA .
CARCINOGENESIS, 1991, 12 (03) :521-524
[36]   Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland [J].
Misra, RR ;
Tangrea, JA ;
Virtamo, J ;
Ratnasinghe, D ;
Andersen, MR ;
Barrett, M ;
Taylor, PR ;
Albanes, D .
CANCER LETTERS, 2001, 164 (02) :161-167
[37]  
MORISHITA K, 1987, J BIOL CHEM, V262, P15208
[38]   Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis [J].
Nagra, RM ;
Becher, B ;
Tourtellotte, WW ;
Antel, JP ;
Gold, D ;
Paladino, T ;
Smith, RA ;
Nelson, JR ;
Reynolds, WF .
JOURNAL OF NEUROIMMUNOLOGY, 1997, 78 (1-2) :97-107
[39]   BIOCHEMICAL AND IMMUNOLOGICAL ANALYSIS OF HEREDITARY MYELOPEROXIDASE DEFICIENCY [J].
NAUSEEF, WM ;
ROOT, RK ;
MALECH, HL .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (05) :1297-1307
[40]   Insights into myeloperoxidase biosynthesis from its inherited deficiency [J].
Nauseef, WM .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1998, 76 (10) :661-668